Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2016

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2016


  • Products Id :- GMDHC8449IDB
  • |
  • Pages: 87
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2016', provides an overview of the Paroxysmal Nocturnal Hemoglobinuria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Paroxysmal Nocturnal Hemoglobinuria

- The report reviews pipeline therapeutics for Paroxysmal Nocturnal Hemoglobinuria by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Paroxysmal Nocturnal Hemoglobinuria therapeutics and enlists all their major and minor projects

- The report assesses Paroxysmal Nocturnal Hemoglobinuria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Paroxysmal Nocturnal Hemoglobinuria

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Paroxysmal Nocturnal Hemoglobinuria pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Paroxysmal Nocturnal Hemoglobinuria Overview 8

Therapeutics Development 9

Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Overview 9

Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Development by Companies 10

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Paroxysmal Nocturnal Hemoglobinuria - Products under Development by Companies 13

Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development 14

Achillion Pharmaceuticals, Inc. 14

Akari Therapeutics, Plc 15

Alexion Pharmaceuticals Inc 16

Alnylam Pharmaceuticals, Inc. 17

Amgen Inc. 18

Amyndas Pharmaceuticals LLC 19

Apellis Pharmaceuticals Inc 20

Epirus Biopharmaceuticals, Inc. 21

Novartis AG 22

Omeros Corporation 23

Ra Pharmaceuticals, Inc. 24

Regenesance BV 25

The International Biotechnology Center (IBC) Generium 26

Paroxysmal Nocturnal Hemoglobinuria - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

ACH-4471 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

ALN-CC5 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

ALXN-1210 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

AMY-101 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

APL-2 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

APL-9 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Coversin - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

eculizumab biosimilar - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

eculizumab biosimilar - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

GNR-045 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Monoclonal Antibody for Paroxysmal Nocturnal Hemoglobinuria - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

NM-9405 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

OMS-721 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

OMS-906 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

RA-101348 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

RA-101495 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

regenemab - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Synthetic Peptide to Target Complement C3 for Immunology, PNH and CNS Disorders - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Synthetic Peptides to Inhibit Factor D for Age-Related Macular Degeneration, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

tesidolumab - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Paroxysmal Nocturnal Hemoglobinuria - Dormant Projects 73

Paroxysmal Nocturnal Hemoglobinuria - Discontinued Products 74

Paroxysmal Nocturnal Hemoglobinuria - Product Development Milestones 75

Featured News & Press Releases 75

Aug 10, 2016: Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy in Paroxysmal Nocturnal Hemoglobinuria Model 75

Aug 04, 2016: Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Blockade of the Alternative Pathway of Complement System 75

Jul 13, 2016: Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria 76

Jul 12, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria 76

Jul 06, 2016: Akari Therapeutics Announces Positive Interim Update from Phase Ib Trial Demonstrating Sustained Complement Inhibition Using Once-Daily Subcutaneous Maintenance Dosing with Coversin 77

Jun 23, 2016: Apellis Announces Positive Results from Phase 1 Clinical Trials of APL-2, a C3 Complement Inhibitor 77

Jun 10, 2016: Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association 78

Jun 10, 2016: Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH 79

Jun 10, 2016: Ra Pharmaceuticals Presents Clinical Data on Complement C5 Inhibitor RA101495 at the 21st Congress of the European Hematology Association 81

Jun 01, 2016: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) 82

May 19, 2016: Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association 83

May 19, 2016: Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress 84

May 19, 2016: Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated 84

May 19, 2016: Ra Pharmaceuticals to Present at the 21st Congress of the European Hematology Association 85

May 09, 2016: EPIRUS Announces Reprioritization of Pipeline, to focus on biosimilar product BOW080 86

Appendix 87

Methodology 87

Coverage 87

Secondary Research 87

Primary Research 87

Expert Panel Validation 87

Contact Us 87

Disclaimer 88

List of Figures

Number of Products under Development for Paroxysmal Nocturnal Hemoglobinuria, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Targets, H2 2016 28

Number of Products by Stage and Targets, H2 2016 28

Number of Products by Mechanism of Actions, H2 2016 30

Number of Products by Stage and Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Top 10 Molecule Types, H2 2016 34

List of Tables

Number of Products under Development for Paroxysmal Nocturnal Hemoglobinuria, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016 14

Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Akari Therapeutics, Plc, H2 2016 15

Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 16

Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 17

Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Amgen Inc., H2 2016 18

Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016 19

Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Apellis Pharmaceuticals Inc, H2 2016 20

Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016 21

Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Novartis AG, H2 2016 22

Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Omeros Corporation, H2 2016 23

Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Ra Pharmaceuticals, Inc., H2 2016 24

Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Regenesance BV, H2 2016 25

Paroxysmal Nocturnal Hemoglobinuria - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Paroxysmal Nocturnal Hemoglobinuria - Dormant Projects, H2 2016 73

Paroxysmal Nocturnal Hemoglobinuria - Discontinued Products, H2 2016 74

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Achillion Pharmaceuticals, Inc.

Akari Therapeutics, Plc

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc.

Amgen Inc.

Amyndas Pharmaceuticals LLC

Apellis Pharmaceuticals Inc

Epirus Biopharmaceuticals, Inc.

Novartis AG

Omeros Corporation

Ra Pharmaceuticals, Inc.

Regenesance BV

The International Biotechnology Center (IBC) Generium

Paroxysmal Nocturnal Hemoglobinuria Therapeutic Products under Development, Key Players in Paroxysmal Nocturnal Hemoglobinuria Therapeutics, Paroxysmal Nocturnal Hemoglobinuria Pipeline Overview, Paroxysmal Nocturnal Hemoglobinuria Pipeline, Paroxysmal Nocturnal Hemoglobinuria Pipeline Assessment

select a license

Single User License
USD 2000 INR 128700
Site License
USD 4000 INR 257400
Corporate User License
USD 6000 INR 386100

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com